As Drumond Rennie put it, ‘Science does not come alive until it is shared publicly’ (1998), emphasising that the rapid advancement of scientific research requires its efficient and rigorous dissemination both to encourage the development of new strategies and to avoid duplication of effort and resources. The current model of scientific and technological research is facing a significant challenge: the cost associated with publishing its results. It is now increasingly common for publishers to impose fees on the scientific community to publish their results, generating debate about the impact of this practice on the fairness of scientific dissemination. Requiring researchers to pay publication costs would limit or exclude research from countries with limited resources, creating significant barriers to the dissemination of knowledge. It has been estimated that costs in some cases are up to ten times higher than what is considered adequate to cover the actual costs of publication (Grossmann & Brembs, 2021). This mismatch raises questions about the justification for such fees and the benefits to funders, given that the funds are often public, or even come from researchers' own pockets. Moreover, this current model supports a highly lucrative publishing industry, valued at approximately $10 billion (Global $10B Scientific & Technical Publishing Industry Report, 2019-2023), and is possibly one of the main causes of the emergence of so-called Predatory Journals. These journals, sometimes described as fraudulent, appear to be legitimate journals, but in reality distort certain publication practices, with a purely profit-driven ultimate purpose (Elmore & Weston, 2020), representing an ethical violation by exploiting the need of researchers for financial gain without providing true scientific value. Given the current landscape, it is crucial to reflect on how these practices affect equity in the dissemination of scientific knowledge?, and how publishing power can limit the dissemination of research on specific pathologies in emerging countries, restricting the right of communities to access crucial information and develop effective public health policies?. Undoubtedly, equity of access to and distribution of scientific knowledge is a fundamental principle that must be strongly defended. Paying high costs for scientific and technological publication not only jeopardises equal opportunities for researchers from regions with fewer resources, but also affects fairness in the distribution of knowledge. This economic barrier can result in a systematic exclusion of relevant perspectives and data from emerging countries, deepening inequalities and limiting global progress in critical areas such as public health. Consequently, there is a need to re-examine the current publication model to ensure that science continues to advance in a way that is fair and accessible to all, and to ensure that information vital to public health and scientific progress is not restricted by economic barriers, but is based on principles of fairness and transparency. Indeed, the scientific community must work together to promote the dissemination of knowledge in a manner that is accessible, equitable and free from harmful practices.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.31053/1853.0605.v81.n4.46392 | DOI Listing |
Nephrol Nurs J
January 2025
Research Associate Professor of Biostatistics, Department of Biostatics and Computational Biology, University of Rochester Medical Center, Rochester, NY.
Whether pediatric dialysis is morally obligatory is an ethical issue. The study's aim was to understand neonatal and pediatric intensive care unit (ICU) nurses' beliefs regarding the ethical use of pediatric dialysis. A single center study was conducted using theoretical and case-based surveys.
View Article and Find Full Text PDFNephrol Nurs J
January 2025
Professor of Medicine, Department of Internal Medicine, Division of Nephrology, School of Medicine, Virginia Commonwealth University.
Chronic kidney disease (CKD) affects 10% of the global population, with increasing prevalence driven by diabetes, hypertension, and aging populations. CKD often progresses asymptomatically, frequently undetected until advanced stages, and may require costly treatments, such as dialysis or transplantation. CKD imposes a substantial financial burden on health care systems, with management costs rising sharply as the disease progresses, underscoring the need for early, cost-effective interventions.
View Article and Find Full Text PDFSmall
January 2025
Chongqing Key Laboratory of Prevention and Treatment for Occupational Diseases and Poisoning, First Affiliated Hospital of Chongqing Medical and Pharmaceutical College, Chongqing, 400060, China.
Nanozyme-based colorimetric sensors are promising approaches for environmental monitoring, food safety, and medical diagnostics. However, developing novel nanozymes that exhibit high catalytic activity, good dispersion in aqueous solution, high sensitivity, selectivity, and stability is challenging. In this study, for the first time, single-atom iridium-doped carbon dot nanozymes (SA Ir-CDs) are synthesized via a simple in situ pyrolysis process.
View Article and Find Full Text PDFObjectives: This report describes changes in total, early, and late fetal mortality between 2022 and 2023 (provisional), as well as fetal mortality by maternal race and Hispanic origin and state of residence. Comparisons are made with findings from 2021 to 2022.
Methods: Data are based on reports of fetal death filed in the 50 states and the District of Columbia and collected via the National Vital Statistics System.
Biometrics
January 2025
Department of Statistics and Data Science, National University of Singapore, Singapore 117546, Singapore.
Pharmacogenomics stands as a pivotal driver toward personalized medicine, aiming to optimize drug efficacy while minimizing adverse effects by uncovering the impact of genetic variations on inter-individual outcome variability. Despite its promise, the intricate landscape of drug metabolism introduces complexity, where the correlation between drug response and genes can be shaped by numerous nongenetic factors, often exhibiting heterogeneity across diverse subpopulations. This challenge is particularly pronounced in datasets such as the International Warfarin Pharmacogenetic Consortium (IWPC), which encompasses diverse patient information from multiple nations.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!